---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Special populations"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Special populations. Topics: Participants aged 65 years and older in the phase 3 trials; Renal impairment; Hepatic and renal impairment: regulatory expectation for dedicated studies; Hepatic function, cardiovascular disease, and seizure disorders as exclusions in the COMP360 pharmacokinetic study; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Participants aged 65 years and older in the phase 3 trials

| Trial and arm | Age, years, minimum and maximum | Age 65 years or older, n (%) |
| --- | --- | --- |
| COMP005, COMP360 25 mg (N=171) | “19, 77” | “15 (8.8)” |
| COMP005, placebo (N=87) | “22, 72” | “11 (12.6)” |
| COMP006, COMP360 25 mg (N=296) | “18, 79” | “29 (9.8)” |
| COMP006, COMP360 10 mg (N=142) | “19, 73” | “9 (6.3)” |
| COMP006, COMP360 1 mg (N=143) | “20, 75” | “13 (9.1)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.8-2"></a>

### Renal impairment

> “The small amount of psilocin renally excreted suggests that no dose reduction is needed for subjects with mild-moderate renal impairment.”

Source: [Brown et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28353056/)

> “The renal clearance of psilocin was 42 ± 30 mL/min.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.8-3"></a>

### Hepatic and renal impairment: regulatory expectation for dedicated studies

> “Sponsors should evaluate the pharmacokinetics of a psychedelic drug in patients with impaired renal function and patients with impaired hepatic function to provide dose adjustment recommendations and inform labeling.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.8-4"></a>

### Hepatic function, cardiovascular disease, and seizure disorders as exclusions in the COMP360 pharmacokinetic study

> “Participants with AST, ALT, gamma-glutamyl transferase (GGT) or total bilirubin levels ≥1.5 x the ULN at Screening (V1) or day -1 (V2).”
> “Current or previous medical history of any cardiovascular conditions.”
> “Current or previous medical history of epilepsy or the presence of other medical conditions associated with seizures or convulsions.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy and breastfeeding

> “Women of childbearing potential who are pregnant, breastfeeding, or planning to conceive.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

> “women of childbearing potential not using adequate contraception; women who were pregnant or breastfeeding”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-2.1.2.8-6"></a>

### Psychiatric and treatment-history exclusions in the phase 3 trials

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”
> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-2.1.2.8-7"></a>

### Regulatory expectation for representative trial populations

> “Trials should not unnecessarily exclude subjects who have certain health characteristics (e.g., age, treatment history, concurrent treatments, pregnancy) if these groups are intended to receive the treatment post-approval, but they should be appropriately stratified.”
> “Excluded populations may not be described in the approved indication in prescribing information.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
